Welcome back to Digital Trials Digest — ObvioHealth's quarterly look at what's new in ObvioGo, where the industry is heading, and the partnerships shaping the future of decentralized trials. This quarter, we're delivering on what we teased last issue, and looking ahead to what's coming next.

Product spotlight: Image Capture and Central Rating

ObvioGo's latest release introduces new capabilities for visual and document-based data capture and independent expert review, supporting more complex, endpoint-driven study designs:

• Image and file uploads within study activities. Participants can now upload images and files directly within a study activity, enabling visual and document-based data capture natively in ObvioGo.
• Manual redaction for photo file upload. Study teams can now manually redact personally identifiable information (PII) — such as faces, names, or other identifying details — from participant-submitted photos. A three-tier classification system (Restricted, Non-PII, and Conditionally PII with a review step) applies these protections by design, supporting privacy and regulatory requirements for image-based data.
• Central Rating. Independent, blinded expert raters can now review and score participant-submitted images and files before an activity is marked complete, with a dedicated dashboard, media viewer, structured rating input, and full audit trail. Submissions are stored securely, and ratings are processed in parallel with the participant's workflow to help minimize delays.

Why it matters: Built for dermatology, wound care, injection-site reactions, ophthalmology, identification documents, and other studies requiring visual evidence, these features address one of decentralized trials' most persistent challenges — capturing and reviewing visual data without relying entirely on site-based processes.

Explore Image Capture & Central Rating →

Research & partner spotlight

SPRIM PRO, ObvioHealth's clinical operations partner, published new research this quarter providing evidence that caregivers, when guided remotely, can measure infant growth as reliably as clinical staff.

In a study published in Frontiers in Pediatrics, SPRIM PRO's clinical science team compared caregiver-collected weight, length, and head circumference measurements — taken at home with telehealth guidance from a study nurse — against measurements taken by pediatric healthcare providers and neonatal nurses. Across all three measurements and all groups, reliability coefficients ranged from 0.97 to 1.00.

SPRIM PRO and ObvioHealth shared these findings together in a co-hosted webinar on September 17, alongside guidance on maximizing electronic observer-reported outcome (eObsRO) diary compliance and at-home biospecimen collection in decentralized trials.

Why it matters: These findings provide published evidence supporting a caregiver-guided, telehealth-supported approach to at-home growth monitoring. SPRIM PRO provides the clinical oversight, remote guidance, and device expertise, while ObvioGo supports participant data capture and real-time growth review. Planned OG-2.10 enhancements — including longitudinal comparisons and recurring workflows that stop once defined protocol criteria are met — are particularly relevant to Growth & Tolerance studies.

Industry perspective: the EDC can change. The participant experience shouldn't.

Sponsors select an EDC based on regulatory requirements, data management needs, and existing technology investments. Participants need one thing to stay constant: a simple, consistent way to consent, complete study activities, report outcomes, and stay connected with the study team.

ObvioGo separates the participant experience from the systems operating behind it. Participants engage through a consistent participant-facing experience, while mapped study data flows directly into supported EDC systems. Connectivity with Oracle Clinical One is already established, and Veeva EDC integration is coming with OG-2.10, so sponsors can maintain the systems they trust without creating disconnected workflows for participants or unnecessary data re-entry for study teams.

The goal is not another system to manage. It is a consistent participant-facing experience designed to work across supported EDC ecosystems — making hybrid and decentralized studies easier to run and easier to participate in.

Coming soon in ObvioGo

• Participant Web Experience. OG-2.10 will introduce a browser-based version of the full ObvioGo participant experience. Participants will be able to join a study, consent, and complete study activities through a supported web browser, without downloading the mobile app — removing a longstanding barrier for short-term, questionnaire-based study designs.
• Live Chat, rebuilt natively. ObvioGo's live chat is getting a complete native rebuild: real-time messaging between participants and study teams, manual PII redaction from messages before export, complete chat history for authorized study team members regardless of when they joined the study, and push notifications on mobile and Participant Web.
• Veeva EDC integration. With OG-2.10, ObvioGo's native EDC connectivity will extend to Veeva. Participant-submitted data — including parent and child activities, electronic signatures, and repeatable tables — will sync directly into a sponsor's Veeva casebook, with automatic conflict checks flagging site, visit, or form mismatches before they can block a submission. OG-2.10 will also introduce a dedicated Integrations workspace in Study Manager for managing configurations, reviewing conflicts, and monitoring synchronization activity.
• Protocol logic, leveled up. ObvioGo's conditional logic will expand to support more sophisticated longitudinal workflows: comparing a participant's current response with responses from previous occurrences, Helper Variables that update automatically as activities are completed, and stopping rules for recurring workflows once defined protocol criteria have been met. Separate workflow paths for expired or missed activities will let designers distinguish between participants who completed an activity and those who missed it.

Why it matters: Together, these capabilities give sponsors more flexibility in how participants access a study, communicate with study teams, and submit data into the sponsor's existing EDC environment — and give study teams more control over longitudinal logic, particularly relevant for Growth & Tolerance and similar study designs.

Company news: PR & media highlights

Patient Monitoring and Clinical Support

ObvioHealth and SPRIM PRO announced a new integrated Patient Monitoring and Clinical Support solution on September 10, pairing the ObvioGo platform with SPRIM PRO's 25+ years of clinical operations and patient-support experience into a single, configurable program for REMS (Risk Evaluation and Mitigation Strategy) programs, specialty therapeutics, advanced biologics, cell and gene therapies, and infusion therapies.

The combined offering pairs ObvioGo's digital symptom reporting, telehealth capabilities, configurable escalation pathways, and real-time data visibility with SPRIM PRO's clinical review and triage, patient education, clinical oversight, and device and supply logistics.

Why it matters: As specialty and other high-risk, high-touch therapies make up a growing share of new drug approvals, sponsors need monitoring and support that goes beyond a standalone app — and this partnership positions ObvioGo and SPRIM PRO to offer both pieces as one program.

Explore Patient Monitoring & Clinical Support →

Upcoming events

• LSI Europe — September 28–October 1, Barcelona, Spain
• AusBiotech International Conference — October 21–23, Gold Coast, Australia

Download the full Q3 2026 issue (PDF) →

That's Q3 from ObvioHealth. If ObvioGo belongs in your next study, let's talk.